R59- GERN, and this board
Re, this board almost never play the stocks I tout. I mean last year, how many on the board played SQQQ ? How many on the board owned HZNP in 2020-2022, while the stock went up 500% ! How many played AAOI from $20 to $100 in 2017, or BNGO from $3 to $13 in 2020-2021, or at least 10 others that were multibaggers that I touted ! Point is, GERN has the best drug(Imetelstat) for treating low risk MDS in the world, in which estimated revenues are $3B/year by 2030. Sqibbs Rebolzyl only treats 1/4 the low risk MDS population, while Imetelstat treats 100%. At the same time, Imetelstat respondents have been infusion free for 6+ months for one group, and 1+ years for the other group. The way I see it is, GERN will either not get FDA approval, and tank 80%, or get FDA approval and get bought out for $7-$12. Re, the fact that GERN short interest is rising from 5%-6% means very little IMO, and could easily be manipulation so that more Institutions can buy cheap. The way I see it is, GERN has the best drug, Institutions are buying more, and price targets are rising. I believe the risk reward is worth it for a best in breed drug candidate.
